Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models

Gynecologic Oncology

Volumn 138, Issue 1, 2015, Pages 165-173

  Schrauwen, Stefanie ^a   Depreeuw, Jeroen ^a,b,c   Coenegrachts, Lieve ^a   Hermans, Els ^a   Lambrechts, Diether ^b,c   Amant, Frédéric ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

AZD6244; Endometrioid endometrial cancer; NVP BEZ235; Primary cell culture; Targeted therapy

Indexed keywords

BUPARLISIB; CARBOPLATIN; DACTOLISIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN S6; RAF PROTEIN; RAS PROTEIN; SELUMETINIB; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MTOR PROTEIN, HUMAN; QUINOLINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MODEL; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIMARY ENDOMETRIOID ENDOMETRIAL CARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, ENDOMETRIOID; DRUG EFFECTS; DRUG SCREENING; ENDOMETRIAL NEOPLASMS; ENZYMOLOGY; METABOLISM; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; CARCINOMA, ENDOMETRIOID; DRUG SYNERGISM; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMIDAZOLES; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLINES; RAF KINASES; RAS PROTEINS; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84931560371     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.04.028     Document Type: Article

References (39)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J. Clin. 64 2014 9 29
2. J.I. Sorosky Endometrial cancer Obstet. Gynecol. 120 2012 383 397
3. F. Amant, P. Moerman, P. Neven, D. Timmerman, L.E. Van, and I. Vergote Endometrial cancer Lancet 366 2005 491 505
4. G. Emons, and W. Heyl Hormonal treatment of endometrial cancer J. Cancer Res. Clin. Oncol. 126 2000 619 623
5. C.E. Humber, J.F. Tierney, R.P. Symonds, M. Collingwood, J. Kirwan, and C. Williams Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration Ann. Oncol. 18 2007 409 420
6. H.B. Salvesen, I.S. Haldorsen, and J. Trovik Markers for individualised therapy in endometrial carcinoma Lancet Oncol. 13 2012 e353 e361
7. T.F. Cloughesy, K. Yoshimoto, P. Nghiemphu, K. Brown, J. Dang, and S. Zhu Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma PLoS Med. 5 2008 e8
8. M.C. Mendoza, E.E. Er, and J. Blenis The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation Trends Biochem. Sci. 36 2011 320 328
9. A.M. Oza, L. Elit, M.S. Tsao, S. Kamel-Reid, J. Biagi, and D.M. Provencher Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group J. Clin. Oncol. 29 2011 3278 3285
10. I. Ray-Coquard, L. Favier, B. Weber, C. Roemer-Becuwe, P. Bougnoux, and M. Fabbro Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO Br. J. Cancer 108 2013 1771 1777
11. H.J. Mackay, E.A. Eisenhauer, S. Kamel-Reid, M. Tsao, B. Clarke, and K. Karakasis Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer Cancer 120 2014 603 610
12. L.S. Bradford, A. Rauh-Hain, R.M. Clark, J.W. Groeneweg, L. Zhang, and D. Borger Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer Gynecol. Oncol. 133 2014 346 352
13. S.M. Maira, S. Pecchi, A. Huang, M. Burger, M. Knapp, and D. Sterker Identification and characterization of NVP-BKM120, an orally available pan class I PI3-Kinase inhibitor Mol. Cancer Ther. 11 2012 317 328
14. J.C. Bendell, J. Rodon, H.A. Burris, M. de Jonge, J. Verweij, and D. Birle Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors J. Clin. Oncol. 30 2012 282 290
15. J. Rodon, I. Brana, L.L. Siu, M.J. De Jonge, N. Homji, and D. Mills Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors Invest. New Drugs 32 2014 670 681
16. S.M. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell, and C. Fritsch Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity Mol. Cancer Ther. 7 2008 1851 1863
17. K. Shoji, K. Oda, T. Kashiyama, Y. Ikeda, S. Nakagawa, and K. Sone Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas PLoS One 7 2012 e37431
18. S.M. Maira, F. Stauffer, C. Schnell, and C. Garcia-Echeverria PI3K inhibitors for cancer treatment: where do we stand? Biochem. Soc. Trans. 37 2009 265 272
19. T.C. Yeh, V. Marsh, B.A. Bernat, J. Ballard, H. Colwell, and R.J. Evans Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor Clin. Cancer Res. 13 2007 1576 1583
20. R.D. Carvajal, J.A. Sosman, J.F. Quevedo, M.M. Milhem, A.M. Joshua, and R.R. Kudchadkar Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial JAMA 311 2014 2397 2405
21. H.S. Hochster, N. Uboha, W. Messersmith, P.J. Gold, B.H. ONeil, and D. Cohen Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer Cancer Chemother. Pharmacol. 75 2015 17 23
22. M. Paolo, S. Assunta, R. Antonio, S.P. Claudia, B.M. Anna, and S. Clorinda Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC Rev. Recent Clin. Trials 8 2013 93 100
23. P.L. Bedard, J. Tabernero, F. Janku, Z.A. Wainberg, L. Paz-Ares, and J. Vansteenkiste Ph lb dose escalation study of oral pan-PI3K inhibitor buparlisib (BKM120) with oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with advanced solid tumours Clin. Cancer Res. 21 2015 730 738
24. J.S. Khalili, X. Yu, J. Wang, B.C. Hayes, M.A. Davies, and G. Lizee Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant Clin. Cancer Res. 18 2012 4345 4355
25. T. Shimizu, A.W. Tolcher, K.P. Papadopoulos, M. Beeram, D.W. Rasco, and L.S. Smith The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer Clin. Cancer Res. 18 2012 2316 2325
26. S. Schrauwen, L. Coenegrachts, J. Depreeuw, C. Luyten, G. Verbist, and D. Debruyne Microsatellite instable and microsatellite stable primary endometrial carcinoma cells and their subcutaneous and orthotopic xenografts recapitulate the characteristics of the corresponding primary tumor Int. J. Gynecol. Cancer 25 2015 363 371
27. C. Maletzki, S. Stier, U. Gruenert, M. Gock, C. Ostwald, and F. Prall Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas PLoS One 7 2012 e52485
28. M.L. Sos, K. Michel, T. Zander, J. Weiss, P. Frommolt, and M. Peifer Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions J. Clin. Invest. 119 2009 1727 1740
29. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev. 58 2006 621 681
30. T. Oishi, H. Itamochi, A. Kudoh, M. Nonaka, M. Kato, and M. Nishimura The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma Oncol. Rep. 32 2014 553 558
31. M.M. Kirstein, A.E. Boukouris, D. Pothiraju, L.E. Buitrago-Molina, S. Marhenke, and J. Schutt Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma Liver Int. 33 2013 780 793
32. B.R. Davies, A. Logie, J.S. McKay, P. Martin, S. Steele, and R. Jenkins AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models Mol. Cancer Ther. 6 2007 2209 2219
33. J.J. Tentler, S. Nallapareddy, A.C. Tan, A. Spreafico, T.M. Pitts, and M.P. Morelli Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer Mol. Cancer Ther. 9 2010 3351 3362
34. H. Zhong, C. Sanchez, D. Spitrzer, S. Plambeck-Suess, J. Gibbs, and W.G. Hawkins Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models PLoS One 8 2013 e77243
35. T. Fuereder, T. Wanek, P. Pflegerl, A. Jaeger-Lansky, D. Hoeflmayer, and S. Strommer Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake Clin. Cancer Res. 17 2011 5322 5332
36. B. Geoerger, K. Kerr, C.B. Tang, K.M. Fung, B. Powell, and L.N. Sutton Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy Cancer Res. 61 2001 1527 1532
37. d.G. Moon, S.E. Lee, M.M. Oh, S.C. Lee, S.J. Jeong, and S.K. Hong NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells Int. J. Oncol. 45 2014 1027 1035
38. F. Yang, X.J. Qian, W. Qin, R. Deng, X.Q. Wu, and J. Qin Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma PLoS One 8 2013 e59879
39. L. Chang, P.H. Graham, J. Hao, J. Ni, J. Bucci, and P.J. Cozzi PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways Cell Death Dis. 5 2014 e1437